Rxi Nabs RNAi Grants

RXi has been awarded over $500K from the NIH, in part to fund efforts to develop an RNAi treatment for ALS. An additional $1 million in funding (http://contractresearch.pharmaceutical-business-review.com/news/mlsc-funds-umms-rxi-pharma-to-develop-new-als-treatment-290411) from The Massachusetts Life Sciences Center has supported RXi’s work on silencing the SOD1 gene.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail